Brief: Sumitomo Pharma America Announces That Its Investigational Therapy Dsp-3077 Has Received FDA Orphan Drug Designation For The Treatment Of Retinitis Pigmentosa
23/03/2026 12:10
Sumitomo Pharma Co Ltd 4506.T: SUMITOMO PHARMA AMERICA ANNOUNCES THAT ITS INVESTIGATIONAL THERAPY DSP-3077 HAS RECEIVED FDA ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF RETINITIS PIGMENTOSA Source text: ID:nPn2WYLDJa Further company coverage: 4506.T
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)